883985-18-0Relevant articles and documents
Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases
Plé, Patrick A.,Jung, Frédéric,Ashton, Sue,Hennequin, Laurent,Laine, Romuald,Morgentin, Rémy,Pasquet, Georges,Taylor, Sian
scheme or table, p. 262 - 266 (2012/02/16)
A new series of Quinazoline Ether Inhibitor which potently inhibits VEGFR-2 and PDGFR tyrosine kinases is described here. In vitro, pharmacokinetics and in vivo evaluations led to the selection of AZD2932.
QUINAZOLINE DERIVATIVES
-
Page/Page column 91, (2008/06/13)
The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.